DURLAZA (aspirin) by Bayer is [acetylsalicylic acid (asa)] inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their lifespan of about 7-10 days. Approved for coronary artery disease, acute ischemic stroke, myocardial infarction and 2 more indications. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
DURLAZA is an extended-release oral aspirin (acetylsalicylic acid) approved in 2015 for cardiovascular indications including coronary artery disease, acute ischemic stroke, myocardial infarction, and acute coronary syndrome. It works by irreversibly inhibiting COX-1 and blocking platelet aggregation for 7–10 days through suppression of thromboxane A2 synthesis. The extended-release formulation provides sustained antiplatelet effects with a single daily dose.
Product is in peak commercial phase with established market presence, but faces moderate competitive pressure (30/100) requiring strong field execution and managed care positioning.
[acetylsalicylic acid (ASA)] inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their lifespan of about 7-10 days. The acetyl group of aspirin binds with a serine residue of cyclooxygenase-1 (COX-1) , resulting in irreversible inactivation of the enzyme. Inhibition…
Worked on DURLAZA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
With only 1 linked job and minimal linked headcount, DURLAZA represents a maintenance-stage product with limited team expansion opportunities. Careers on this brand focus on consolidating market share, managing competitive threats, and optimizing payer access rather than building new franchises.
1 open roles linked to this drug